Peter Lichtlen

Peter is the Chief Medical Officer and is a co-founder of Numab. He holds an MD as well as a PhD in Molecular Biology from the University of Zurich. In 2000 Peter joined ESBATech AG where he led several preclinical and clinical development projects with antibody fragments in oncology, inflammatory and neurodegenerative diseases as the Head of clinical R&D. In particular, he designed the clinical proof-of-concept trial for brolucizumab/Beovu® in wet age-related macular degeneration. In 2011 Peter joined Sucampo Pharmaceuticals, where he became the company’s Chief Medical Officer. In this function, he managed the global clinical development portfolio and held overall responsibility for Medical Affairs and Pharmacovigilance and had numerous interactions with major regulatory agencies as well as HTA bodies, leading to successful NDAs, MAAs and STAs. After the acquisition by Mallinckrodt in 2018, Peter joined Numab as full-time Chief Medical Officer.